Significant Ownership of Affinity Asset Advisors, LLC

Signature - Title
/s/ Andrew Weinstein - Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Affinity Asset Advisors, LLC.

Notify me when Affinity Asset Advisors, LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Affinity Asset Advisors, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
IBIO iBio, Inc. Common Stock, par value $0.001 per share 9.99% $2.51M 2.18M Affinity Asset Advisors, LLC Aug 19, 2025
KPTI Karyopharm Therapeutics Inc. Common Stock, par value $0.0001 per share 7.83% $4.22M 664K Affinity Healthcare Fund, LP Apr 3, 2025
STRO SUTRO BIOPHARMA, INC. Common Stock, par value $0.001 per share 7.77% $5.72M 6.58M Affinity Healthcare Fund, LP Oct 16, 2025
LXEO Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share 7.75% $12.7M 4.25M Affinity Healthcare Fund, LP May 28, 2025
AVTX Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share 7.65% $12.8M $5.79M 1.01M +82.7% Affinity Healthcare Fund, LP Sep 30, 2025
NXTC NextCure, Inc. Common Stock, par value $0.001 per share 7.17% $1.12M 192K Affinity Healthcare Fund, LP Sep 30, 2025
VTYX Ventyx Biosciences, Inc. Common Stock, par value $0.0001 per share 5.7% $4.91M 4.06M Affinity Healthcare Fund, LP May 22, 2025
VRCA Verrica Pharmaceuticals Inc. Common Stock, $0.0001 par value per share 5.47% $3.42M 884K Affinity Asset Advisors, LLC Nov 25, 2025
INZY Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share 2.89% $2.2M 1.87M Affinity Healthcare Fund, LP May 20, 2025

Schedules 13D/G Reported by Affinity Asset Advisors, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.